Other

Merck + Co., Inc.

The Wellcome Trust Limited As Trustee for the Wellcome Trust

Yoshihiko Kawaguchi

Michael L Metzker

John W Hess

Holly A Hammond

Charles T Caskey

David L Gerhold

Yusuke Nakagawa

Michael S Phillips

Patricia Hey

Tony R Merriman

John A Todd

Roger D Cox

Rebecca C J Twells

Kanenari Gouda

Masaharu Akiyama

Jun Kuroha

Rebecca Cj Twells

Yoshimi Harada

Makoto Miki

Masayuki Tokura

A novel receptor, 'LDL-receptor-related protein-5' ('LRP-5'), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.

Method of screening for modulator of LRP5 activity

A novel receptor, &ldquo;LDL-receptor related protein-3&rdquo; (&ldquo;LRP-3&rdquo;), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.

LDL-receptor

Receptor

Rice-bran wax in the amount of 0.1 to 10 parts by weight per 100 parts of elastomer is added to fluoroelastomers to improve the processability of the fluoroelastomer.

Fluoro-elastomer composition having improved processability

Growing community of inventors

Osaka, Japan

Yoshihiko Kawaguchi